Titre Biomarker Verification in Pediatric Chronic Graft-Versus-Host Disease: Applied Biomarkers to Minimize Long Term Effects of Childhood/Adolescent Cancer Treatment (ABLE) / Pediatric Transplantation & Cellular Therapy Consortium (PTCTC)
Protocole ID ABLE 2.0 /? PTCTC GVH 1901
ClinicalTrials.gov ID NCT04372524
Type(s) de cancer Pédiatrique divers
Phase Autres
Institution CENTRE UNIVERSITAIRE DE SANTE MCGILL
   HOPITAL DE MONTREAL POUR ENFANTS
      1001 boul. Décarie , Montréal, QC, H4A 3J1
Ville Montréal
Investigateur(trice) principal(e) Dr David Mitchell
Coordonnateur(trice) Samira Mezziani
 514-412-4400 poste 22930
Statut Actif en recrutement
Critètes d'éligibilité
  • Any indication for allogeneic hematopoietic stem cell transplant (malignant or non-malignant)
  • Age 0 - 24.99 years at the time of transplant (on day 0)
  • Any conditioning regimen (including myeloablative or reduced-toxicity/reduced-intensity)
  • Any graft source (bone marrow, peripheral blood, cord blood)
  • Any graft-versus-host disease prophylaxis strategy, including serotherapy such as ATG or alemtuzumab
  • Haploidentical transplants, including post-transplant cyclophosphamide and alpha-beta TCR depletion, are allowed
Critètes d'exclusion
  • Second or greater allogeneic transplant
  • Weight 7 kg or less
  • Pure CD34+ selected haploidentical stem cell transplant (not including CD34 enrichment used in alpha-beta TCR depleted haploidentical transplants, which is allowed)
  • Inability of a center to follow a patient for the development of late-acute and chronic GVHD until 1-year post-transplant (referral sites who transplant patients from outside institutions should not enroll participants if sending back to the referring site early, such that long-term follow up, blood, and data collection cannot be assured).